Johnson & Johnson (JNJ) Earnings Date & Reports

Key Takeaways

• Johnson & Johnson reported second-quarter 2026 worldwide sales of $25.31 billion, up 6.6% year over year and above the analyst consensus estimate of roughly $25.06 billion.
• Adjusted diluted earnings per share (EPS) came in at $2.90, topping consensus estimates of about $2.84 by $0.06.
• Innovative Medicine grew 6.8% on an operational basis, led by DARZALEX, TREMFYA, CARVYKTI, and newer neuroscience products, despite heavy pressure from STELARA biosimilar competition.
• Management raised its full-year 2026 outlook, putting the company on track to surpass $100 billion in annual revenue for the first time in its history.
• Shares slipped roughly 1% in premarket trading despite the beat, reflecting investor focus on STELARA erosion and litigation-related expenses.

Earnings Context and Why It Matters

Johnson & Johnson's second-quarter report carries outsized weight because it shows whether the healthcare giant can offset looming patent expirations and biosimilar competition with its newer oncology and immunology franchises. The company has spent years reshaping its portfolio after separating its consumer health business, and investors are watching closely to see if Innovative Medicine and MedTech can sustain momentum. The quarter also serves as a checkpoint on management's ambitious goal of exceeding $100 billion in annual sales. With guidance raised and several newer products growing double digits, the results offer a clearer view of whether J&J's diversification strategy is translating into durable, above-market growth.

Reported Results

For the second quarter ended June 28, 2026, Johnson & Johnson reported worldwide sales of $25.31 billion, a 6.6% increase from $23.74 billion a year earlier and ahead of the consensus estimate near $25.06 billion. Operational sales growth, which excludes the impact of currency translation, was 5.6%.

On a GAAP basis (Generally Accepted Accounting Principles), net earnings were $5.5 billion, or $2.27 per diluted share, essentially flat versus the prior-year period. Adjusted net earnings, which exclude one-time items, rose to $7.1 billion, with adjusted diluted EPS of $2.90, up 4.7% year over year and above the consensus estimate of approximately $2.84.

By segment, Innovative Medicine generated $16.4 billion in sales, up 6.8% on an operational basis, while MedTech delivered $8.9 billion, up 3.6% operationally. Growth was driven by DARZALEX (oncology), TREMFYA (immunology), and SPRAVATO and CAPLYTA (neuroscience), partially offset by a sharp decline in STELARA, which faces biosimilar competition.

The company raised its full-year 2026 guidance. It now expects operational sales growth of 6.5% to 7.1% with a midpoint of about $100.6 billion, and adjusted operational EPS of $11.50 to $11.65, up from its prior range.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking healthcare names like Johnson & Johnson or seeking comparable opportunities across the sector, the AI Screener offers a streamlined way to identify candidates that match specific criteria.

Market Reaction and Investor Sentiment

Despite delivering an earnings and revenue beat, Johnson & Johnson shares traded about 1% lower in premarket activity following the July 15, 2026 release. The muted reaction reflects a market that has grown accustomed to J&J's consistent execution and instead focused on headwinds. STELARA sales fell roughly 55% as biosimilar competition intensified, and the company noted higher litigation and restructuring-related expenses. Investors also weighed a slight decline in adjusted income before tax margins for both segments. Still, sentiment remains broadly constructive, supported by the raised full-year guidance and the company's progress toward a record revenue milestone.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether Johnson & Johnson can sustain its momentum as legacy products face biosimilar erosion. Management expects MedTech growth to accelerate in the second half of the year, and procedure volumes remain stable, which should support that outlook.

A key focus will be the oncology franchise, where DARZALEX continues to post double-digit growth and newer therapies such as CARVYKTI and TECVAYLI are gaining share. Data readouts for pipeline candidates, including IMAAVY, INLEXZO, and milvexian, represent near-term catalysts that could shape the company's long-term growth narrative.

On the cost side, litigation expenses and restructuring charges remain areas to monitor, as they have pressured reported margins. Currency translation is another variable, with management noting a modest reduction in favorable currency assumptions in its updated guidance. Overall, the raised outlook suggests confidence, but continued execution against STELARA headwinds and progress in newer franchises will be central to whether the company clears its $100 billion revenue target.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations